Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Oct;50(3):207-209.
doi: 10.5152/eurasianjmed.2018.17302.

Sulfasalazine-Induced Interstitial Fibrosis

Bugra Kerget  1 , Omer Araz  2 , Elif Yilmazel Ucar  2 , Ozkan Aydin  3 , Metin Akgun  2 , Leyla Saglam  2
Affiliations
Case Reports

Sulfasalazine-Induced Interstitial Fibrosis

Bugra Kerget et al. Eurasian J Med. 2018 Oct.

Abstract

Sulfasalazine has been used in the treatment of inflammatory bowel disease for over 60 years. Although the drug is frequently associated with gastrointestinal adverse effects, pulmonary adverse effects are very rare. Herein, we report a case of interstitial fibrosis resulting from 4-month sulfasalazine therapy for ulcerative colitis in a patient under long-term follow-up in our clinic due to chronic obstructive pulmonary disease.

Keywords: Pulmonary fibrosis; sulfasalazine; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Posterior anterior X-ray images in the fourth month of the treatment with sulfasalazine. The bilateral areas of consolidation amid ground-glass density in all zones, which were most pronounced in the lower zones, and increased fibrotic density bilaterally extending to the pleura in the lower zones.
Figure 2
Figure 2
Patient’s chest X-ray images two months before sulfasalazine therapy only showing evident bronchovascular marking.
Figure 3
Figure 3
High-resolution computer tomogram in the fourth month of treatment with sulfasalazine. Centrilobular and panlobular emphysema in the upper lobes and bilateral fibrotic changes in the basal segments of the lower lobes and sporadic honeycombing are observed.
Figure 4
Figure 4
High-resolution computer tomogram in the fourth month of treatment with sulfasalazine. Centrilobular and panlobular emphysema in the upper lobes and bilateral fibrotic changes in the basal segments of the lower lobes and sporadic honeycombing are observed.
Figure 5
Figure 5
Transbronchial biopsy specimen (hematoxylin-eosin stain; original magnification, ×100). Interstitial fibrosis is observed on the middle lobe.
Figure 6
Figure 6
Masson trichrome (original magnification, ×100); the areas with interstitial fibrosis are shown in green.
Figure 7
Figure 7
Posterior anterior X-ray images after 1 month of the treatment.
See this image and copyright information in PMC

References

    1. Ulubaş B, Şahin G, Özer C, Aydın Ö, Özgür E, Apaydın D. Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. Clin Rheumatol. 2004;23:249–51. https://doi.org/10.1007/s10067-003-0848-5 - DOI - PubMed
    1. Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol. 2011;17:3204–12. - PMC - PubMed
    1. Hamadeh MA, Atkinson J, Smith LJ. Sulfasalazine-induced pulmonary disease. Chest. 1992;101:1033–7. https://doi.org/10.1378/chest.101.4.1033 - DOI - PubMed
    1. Salloum VK, Ancheril S, Estrada-Y-Martin R. Sulfasalazine-induced pulmonary disease. CHEST Journal. 2005;128(4_MeetingAbstracts):447S.
    1. Vennera MC, Picado C. Pulmonary manifestations of inflammatory bowel disease. Arch Bronconeumol. 2005;41:93–8. https://doi.org/10.1016/S1579-2129(06)60404-7 - DOI - PubMed

Publication types

LinkOut - more resources